Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | An overview of novel treatment approaches in TP53-mutated AML

Thomas Cluzeau • 15 Jun 2024
EHA 2024
Leukemia Antibodies CPX-351 Eprenetapopt Magrolimab Sabatolimab Venetoclax

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses novel treatment approaches in patients with TP53-mutated acute myeloid leukemia (AML). To date, clinical trials in this rare and heterogeneous subgroup have been negative, and patients have a poor prognosis, highlighting the urgent need for further investigation into therapeutic options and agents. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Abbvie, BMS, Jazz, Servier, Novartis, Syros.

More from Thomas Cluzeau

iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more 21:29
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
Aditi Shastri et al. • 19 Sep 2025
Novel targets, treatments, and combinations in AML
David Sallman et al. • 29 Sep 2022
Novel treatments & combinations in AML: mechanisms of resistance to venetoclax & approaching R/R disease
Marina Konopleva et al. • 1 Oct 2024
Approaching TP53-mutated MDS and secondary AML
Coleman Lindsley et al. • 16 Jul 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals